POPULARITY
Categories
313 episodes with cancer treatment
111 episodes with cancer treatment
55 episodes with cancer treatment
17 episodes with cancer treatment
42 episodes with cancer treatment
18 episodes with cancer treatment
30 episodes with cancer treatment
34 episodes with cancer treatment
13 episodes with cancer treatment
19 episodes with cancer treatment
18 episodes with cancer treatment
10 episodes with cancer treatment
17 episodes with cancer treatment
14 episodes with cancer treatment
14 episodes with cancer treatment
11 episodes with cancer treatment
16 episodes with cancer treatment
10 episodes with cancer treatment
14 episodes with cancer treatment
9 episodes with cancer treatment
19 episodes with cancer treatment
14 episodes with cancer treatment
26 episodes with cancer treatment
17 episodes with cancer treatment
17 episodes with cancer treatment
17 episodes with cancer treatment
16 episodes with cancer treatment
8 episodes with cancer treatment
6 episodes with cancer treatment
19 episodes with cancer treatment
14 episodes with cancer treatment
6 episodes with cancer treatment
14 episodes with cancer treatment
7 episodes with cancer treatment
7 episodes with cancer treatment
15 episodes with cancer treatment
15 episodes with cancer treatment
10 episodes with cancer treatment
10 episodes with cancer treatment
10 episodes with cancer treatment
17 episodes with cancer treatment
14 episodes with cancer treatment
17 episodes with cancer treatment
16 episodes with cancer treatment
6 episodes with cancer treatment
6 episodes with cancer treatment
124 episodes with cancer treatment
3 episodes with cancer treatment
7 episodes with cancer treatment
6 episodes with cancer treatment
8 episodes with cancer treatment
4 episodes with cancer treatment
6 episodes with cancer treatment
11 episodes with cancer treatment
Paano kung ang pagiging ‘higad' mo brings a big plot twist sa buhay mo that leads to a bigger plot twist? Pakinggan natin ang newest installment ng Kilig Gang Sa Gabi! Be a member on patreon.com/sillygangsagabi for early vidcast release PLUS, ano nga ba ang totoong nangyari kay Mike?! At sino nga ba ang malaki ang chance na ma-raid ng mga pulis?! Panoorin ang nakakalokang Kwentanong! Labanan ang FOMO! Be a Ka-Okra Pro at Pro Max member on patreon.com/sillygangsagabi! Subscribe na dahil part of your subscription goes to our chosen organization for the month of August ang Cancer Treatment & Support Foundation!CERTIFIED KA-OKRA TO DO LIST:✅GIVE THE GIFT OF GOOD VIBES: patreon.com/sillygangsagabi/gift ✅TAP the FOLLOW button and NOTIFICATION BELL here on SPOTIFY RATE this podcast with 5 STARS! ⭐⭐⭐⭐⭐✅Join the GAME for a chance to win Php150! CLICK here to join our FB group
What happens when a 16-year-old boy runs away from chemotherapy—and survives? In this gripping episode of the Nutritional Therapy and Wellness Podcast, Jamie Belz sits down with Billy Best, the teen who became a national sensation in 1994 when he fled conventional cancer treatment in search of something different. Diagnosed with Hodgkin's lymphoma, Billy rejected chemotherapy after watching it ravage his aunt's health and instead placed his trust in faith, intuition, and the wisdom of thousands of everyday people who reached out to introduce him to a whole new world of natural healing. Billy's story is more than a medical anomaly—it's a powerful testimony of medical freedom, holistic healing, and the suppressed potential of natural medicine. His healing protocol included nutritional therapy, Essiac tea, and 714X lymphatic injections, along with a radical mindset shift, spiritual surrender, and a deep belief in the body's ability to heal. Within months, his cancer was gone. Billy didn't just survive. He healed. And in the early days of his recovery, he believed—with everything in him—that his story would change the world. That people would wake up. That natural medicine would finally be heard. That the truth would matter. But it didn't. Instead, Billy faced the crushing reality of censorship, media manipulation, and corporate control. His miraculous outcome wasn't celebrated—it was buried. Stories were pulled at the last minute. Reporters were silenced. And the very system that claims to be searching for a cure wanted nothing to do with the one he'd found. In this episode, you'll discover: The viral true story behind Billy Best's escape from chemotherapy What 714X is, how it works, and why it's banned in the U.S. How bio-individuality, nutrition, and mindset played key roles in his healing The power of belief, faith, and spirituality in the healing process Why Billy believed he'd found the cure for cancer—and what happened when no one wanted it The disturbing link between pharma-funded media, cancer fundraising, and censorship Insight into Codex Alimentarius, glyphosate, GMOs, and the global food agenda Why we must reclaim health freedom and medical sovereignty now more than ever Billy also speaks candidly about the emotional aftermath—how addiction, trauma, and grief shaped the decades following his recovery—and why he's still fighting, 30 years later, to help others awaken, question, and heal. This is more than a survival story. It's a raw, unflinching testimony of what happens when someone dares to trust their gut, break the rules, and walk a path no one else will. And it's a heartbreaking reminder that sometimes, even when you've found the truth, the world just isn't ready for it. Whether you're a practitioner, cancer survivor, or someone seeking health freedom, this conversation is a must-listen. Resources Mentioned: The Nutritional Therapy Association: https://www.nutritionaltherapy.com The Nutritional Therapy and Wellness Podcast Episode with Scott Tips: https://open.spotify.com/episode/4EkpRYFCciDdwZ1A1gIhf7?si=1334c0b3b24e4440 Make a donation to The National Health Federation to help support health freedom: https://thenhf.com/make-a-donation/ Learn more about CODEX: https://thenhf.com/codex/ Checkout Billy's First Book: https://www.amazon.com/Billy-Best-Story-Alternative-Medicine/dp/1937920283/ref=asc_df_1937920283?tag=bingshoppinga-20&linkCode=df0&hvadid=80401987005810&hvnetw=o&hvqmt=e&hvbmt=be&hvdev=c&hvlocint=&hvlocphy=87545&hvtargid=pla-4584001450967570&psc=1&msclkid=5682c8a9fc9d13ffd119a038cedf016a The Billy Best Story (aka the Pasadena Speech) If this episode inspired you, please subscribe, leave a 5-star review, and share it with someone who needs to hear this. Follow us on Spotify and help us keep the conversation going about truth, healing, and health freedom.
Ricardo Carrau, MD, believes cancer patients should consider getting a second opinion before beginning their treatment. “There are multiple reasons to get a second opinion, all of which are correct,” said Carrau, a head and neck cancer surgeon and director of the James Comprehensive Skull Base Surgery Program. “A cancer diagnosis is life changing and if you have any questions, if you want to make sure the decisions you are making are correct, a second opinion is in order.” In this episode, Carrau describes the process, starting with the initial issue that compelled a person to seek medical care. He used his specialty as an example. “A head and neck cancer diagnosis is very complex,” he said. “It begins with a physical exam, endoscopies, then a biopsy and imaging, which is out map of the cancer. Then [here at the James] we have a tumor board, a committee whose members are all experts in all the different areas of head and neck cancer. The end result is taken back to the patient and the patient is the ultimate decision maker; the patient needs to understand the consequences.” It is at this point that Carrau recommends a patient get a second opinion. “There is a perception the physician could be offended by this,” he said. “It isn't that way. The patient and I have a partnership to achieve the best possible outcome … We get a lot of people who come here for a second opinion and some of our patients go elsewhere for a second opinion.” Carrau added that he and other James cancer specialists have a network of expert colleagues at other leading cancer centers they can recommend to their patients for a second opinion. “The reason I went to medical school was to help people,” Carrau said, adding interacting with patients and giving them the best possible care “gives me purpose in life and fulfillment.”
The growing spectrum of neurotoxicities related to targeted cancer therapies can present a challenge for radiologists. In this AJR Conversation, Neuroradiology Imaging Senior Editor Carlos Zamora, MD, PhD, speaks with Alvand Hasankhani, MD, about his team's recently published article addressing the critical role of neuroimaging in detecting and differentiating neurotoxicity syndromes associated with common and emerging cancer therapies.
“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54
Picking up where we left off from the last solo episode. This one goes into everything from initial diagnosis leading up to starting treatment.Thanks for listeningSupport the show
Picking up where we left off from the last solo episode. This one goes into everything from initial diagnosis leading up to starting treatment.Thanks for listeningSupport the show
In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.
In this week's episode of High on Home Grown, we dive into the latest cannabis news from around the world: Macky covers a controversial story out of the U.S., where a power utility company has been reporting suspected cannabis growers to the police based on electricity usage, raising serious questions about privacy and legality. (Ars Technica, via Calyxreefer on Discord) Margaret shares a recent warning from a cannabis doctor who says using weed might weaken the effectiveness of cancer immunotherapy, according to a new study out of New Zealand. (Scimex, via Gdubz on the forum) Billy reports on how Germany's newly legalised cannabis system is bogged down by red tape, with Cannabis Social Clubs facing bureaucratic delays even a year after legalisation. We also discuss the lack of proper cannabis education in medical training programs, leaving future doctors unprepared to prescribe or even understand cannabis therapies. And finally, we highlight concerns around the UK's Online Safety Act and how it could impact cannabis content, communities, and education online. Join us for another packed episode full of global cannabis headlines, medical insights, and policy developments you need to know about. Come and join in the discussion about any of these news articles on our cannabis growing forum, Discord server, or any of your favourite social networks. Visit our website for links.
Welcome to Navigating Cancer TOGETHER, hosted by Talaya Dendy. In this inspiring bonus micro-episode, Talaya shares her personal journey as a cancer survivor, offering hope and encouragement to anyone recently diagnosed with cancer or supporting a loved one through their cancer journey.Discover how hope can be a guiding light through the darkest times, providing strength, comfort, and resilience. Talaya discusses the importance of self-care, surrounding yourself with love, and believing in a brighter future. She emphasizes that you are not alone, many have overcome cancer and emerged stronger, and you can too!✨Key Takeaways:The power of hope in cancer recoveryPractical self-care tips for cancer patientsThe importance of support and communityInspirational stories of overcoming adversityHow to cherish each day and focus on healingTalaya is a seasoned cancer thriver who knows a lot about the various twists end turns one can experinence while facing cancer and beyond. Whether you are facing a cancer diagnosis or supporting someone who is, this micro-episode offers valuable lessons, encouragement, and actionable advice. Tune in to find hope, strength, and a sense of community on your cancer journey.Listen now and let the light of hope guide you through!Transcript: https://bit.ly/podscript_hopeFollow NCT: https://www.linkedin.com/company/navigating-cancer-together
This conversation is an invitation to reconnect with the parts of you that have long been silenced. To reconnect with the truth of who you are. And to feel what your body is really saying through symptoms and sensations. It also serves as a reminder that healing isn't about fixing — it's about coming home to yourself through the power of somatic healing, emotional awareness, and embodied safety. In this transformative episode of HEAL with Kelly, I sit down with my dear friend, Dr. Christian Gonzalez — naturopathic doctor, host of Heal Thy Self, and founder of the Emotional Liberation Method — to explore the powerful connection between the body, trauma, and true healing. I've personally had the honor of working with Dr. G, and I can tell you — his work is nothing short of profound. His understanding of the body, trauma, and emotional expression has shifted the way I see healing, both in myself and in others. From the brilliant role of fascia to the energy of repressed emotion, Dr. G offers a fresh lens on why we get sick — and what it actually takes to get well. Together, we dive into how childhood patterns shape adult identities, how the nervous system underpins nearly every chronic condition, and why voice and vibration — not just breath — may be the missing link in somatic healing. We also touch on the emotional profiles often overlooked in cancer care, the unspoken shame many women carry, the truth about self-abandonment, and how co-regulation can become a portal to profound transformation. Whether you're on a healing journey or simply seeking a deeper understanding of yourself, this conversation is a powerful reminder: What if your chronic symptoms weren't random — but messages from a body that's been trying to speak to you all along? LINKS Dr. Christian Gonzalez Website:https://drchristiangonzalez.com/ Dr. Christian Gonzalez on Instagram:https://www.instagram.com/doctor.gonzalez/ SPONSORS THERASAGE: Go to https://www.therasage.com and use code KELLY to receive 25% off any Therasage product. HONEYLOVE: Go to https://www.honeylove.com/HEAL and use our exclusive link to get 20% OFF. Key Moments You'll Love:
In this heartfelt episode of Me and the Magic, host Amanda Bauner welcomes back Dawn Niebling to share her inspiring journey through breast cancer and how it shaped her most recent Walt Disney World trip with her family. Dawn offers practical tips for vacation planning and self-care during cancer treatment, highlights the emotional and logistical challenges faced, and reflects on the healing power of laughter, positivity, and Disney magic. The episode is filled with honest stories, travel advice, and moments of gratitude, making it a valuable listen for anyone navigating illness while still seeking joy and adventure. Connect with Dawn at dawnatrue@yahoo.com, online on Facebook, or in the Me and the Magic community. Join the Me and the Magic Community Join the Me and the Magic Facebook community to share your love of solo travel, Disney travel, and more with new friends. Plus, share your thoughts and questions on this episode with the community! Connect with Amanda Is there a topic you'd like us to discuss? Email Amanda at amanda@meandthemagic.com. Subscribe to the Me and the Magic weekly newsletter for exclusive content, including solo travel tips! Me and the Magic has voicemail! Leave a voicemail or text to 1-347-74MAGIC (1-347-746-2442). Share your thoughts about this episode, a future episode topic idea, or just say hi! Podcast Subscribe to this podcast so you will be the first to hear new episodes! If you are enjoying the podcast, I'd greatly appreciate it if you could rate and review it on Apple Podcasts. The reviews help other people find this podcast. Online Shop Buy some fun travel and pop culture shirts and more, at our online shop!
AI-boost for mammograms—a bridge too far? Plastics and heart disease; What does a high CRP mean? Social media marketing of female aphrodisiac dinged with FDA warning; Roundup gets a makeover; Artificial sweeteners may hasten puberty in kids; Plus an encore of our interview with Dr. Jeffrey Bland introducing Himalayan Tartary Buckwheat as a hedge against age-related immune decline.
Welcome to episode 201 of Sports Management Podcast. Today's guest is Geoff Thomas MBE – A former professional footballer, cancer survivor and a Patron of charity for Cure Leukaemia. When this episode is live, he just completed all the 21 stages of the Tour the France, raising vital funds for Cure Leukaemia, a cause close to his heart having overcome chronic myeloid leukaemia himself. We spoke about: His background as a professional footballer 9 caps with England without losing Being diagnosed with leukaemia and getting 3 months to live Giving back through charities How Arthrosamid® helped with his knee pain And much more! Time stamps: 00:03 Guest Background & Football Career 03:09 Cancer Diagnosis & Treatment Journey 09:51 Sports Mindset Application to Cancer Treatment 11:54 Tour de France Charity Challenge 15:00 Cure Leukaemia Charity Evolution 19:46 Physical Challenges & Recovery Strategy 21:22 Arthrosamid Knee Treatment 27:09 Mental Health & Support Advice 31:58 Future Goals & Network Follow Sports Management Podcast on social media Instagram Twitter LinkedIn YouTube www.sportsmanagementpodcast.com
The family of a 30-year-old battling a cancer so “horrific” that medical professionals cried while performing radiotherapy is pleading for help with more treatment.Chatham man Alex Able is believed to be the only adult ever recorded in the UK to be diagnosed with the very rare and aggressive Rhabdoid tumour and is now in a race against the clock.Also in today's podcast, you can hear from a Kent campaigner who agrees the system for regulating water companies should be overhauled and Ofwat replaced. It's after a landmark review of the sector outlined 88 recommendations to the government to turn the industry around. A grandmother forced to ‘claw' her way from addiction has reconnected with family thanks to a £4,000 government cash injection.Sarah is among a small group in Kent, being supported by Canterbury-based charity Porchlight, to have joined a first-of-its-kind trial, examining the effects of giving former rough sleepers greater financial help.An animal sanctuary owner says she is “hoping for a miracle” with less than seven weeks before an eviction deadline.Amey James, who runs Happy Pants Ranch, is trying to raise £500,000 to buy the land where she and more than 400 animals live.And in football, the Gillingham manager is confident the goals will come this season - and says ‘don't judge us yet!'You can hear from Gareth Ainsworth after the Gills suffered a 2 – 0 loss to Luton Town in their pre-season friendly.
Join host Talaya Dendy on this special episode of 'Navigating Cancer TOGETHER.' Recorded in honor of National Cancer Survivor Month, this episode features an engaging and heartfelt panel discussion with five incredible cancer survivors: Annamaria Scaccia, Mary Wells, Russ Hedge, Terry Tucker, and Tom Reoach.They candidly reflect on their cancer journeys, the emotional and ongoing nature of survivorship, and the importance of connection, authenticity, and resilience. Tune in for powerful stories, shared wisdom, and practical advice for emotional well-being and rebuilding life that highlights the human side of cancer survivorship. This episode offers hope and insight for newly diagnosed patients, fellow survivors, caregivers, and those offering support.Don't miss these powerful stories. Tune in on Spotify, Apple Podcasts, YouTube, or your preferred podcast platform.
For this week's episode of the Clinician's Corner, we've gone into the archives to pull out another clinical pearl from one of our favorite episodes - and today we discuss the world of integrative cancer care with Dr. Nasha Winters. This interview first aired back in 2023, and the full interview can be viewed here. Clinical pearls we extracted from the original interview: The “cancer terrain” concept and its drivers (Dr. Nasha highlights the top 10) Diet, nutrition, and cancer The modern state of metabolic health - and misconceptions about metabolic markers The role of ketosis and therapeutic diets in cancer Testing and lab assessment for personalized nutrition Therapeutic ketosis in pediatric cases The Clinician's Corner is brought to you by Restorative Wellness Solutions. Follow us: https://www.instagram.com/restorativewellnesssolutions/ Join us for a FREE 3-Part Fertility Masterclass Series: Precision Nutrition for Fertility Grab your spot now! Connect with Dr. Nasha Winters: Website: https://www.drnasha.com Facebook: https://www.facebook.com/drnashainc/ and https://www.facebook.com/mtih.org Instagram: https://www.instagram.com/drnashawinters/ and https://www.instagram.com/mtihorg LinkedIn: https://www.linkedin.com/in/nasha-winters-796374b6/ Twitter: https://twitter.com/drnashawinters and https://twitter.com/MTIH_Terrain YouTube: https://www.youtube.com/c/drnashainc/videos?app=desktop For more information on the Metabolic Terrain Institute of Health: https://mtih.org Additional Resources from Dr. Nasha: Education Resources: https://www.drnasha.com/matcbook/ The Mistletoe Book: https://www.themistletoebook.com MTIH - Practitioner Terrain Network: https://terrain.network/tap/ Timestamps: 00:00 Understanding Cancer's Growing Impact 03:20 "Integrative Cancer Care: Bridging Worlds" 08:29 Toxicity, Microbiome, and Individual Sensitivity 10:55 Circadian Rhythm and Holistic Stressors 13:31 Diet's Impact on Metabolic Health 17:55 Inconsistent Blood Sugar Standards 22:12 "Reevaluating Diet Myths: Fat vs. Sugar" 24:47 Personalized Metabolic Health Strategies 28:21 Alternative Ketosis Methods Explored 32:28 Fertility Masterclass Invitation 35:00 Inaccuracies in Cell Line Studies 37:37 "Ketosis: Impact on Cancer & Epilepsy" 41:53 DIPG Support and Resource Hub 44:07 "Clinician's Corner: Join & Share" Speaker bio: Dr. Nasha Winters is a global healthcare authority and best-selling author in integrative cancer care and research consulting with physicians around the world. She has educated hundreds of professionals in the clinical use of mistletoe and has created robust educational programs for both healthcare institutions and the public on incorporating vetted integrative therapies in cancer care to enhance outcomes. She is currently focused on opening a comprehensive metabolic oncology hospital and research institute in the U.S. where the best that standard of care has to offer and the most advanced integrative therapies will be offered. This facility will be in a residential setting on a gorgeous campus against a backdrop of regenerative farming, EMF mitigation and retreat, as well as state of the art medical technology and data collection and evaluation to improve patient outcomes. Keywords: cancer treatment, metabolic health, integrative medicine, functional health, ketogenic diet, therapeutic ketosis, metabolic flexibility, terrain theory, epigenetics, toxins, microbiome, immune function, inflammation, angiogenesis, blood sugar, insulin resistance, lipid profile, fasting, intermittent fasting, circadian rhythm, stress management, mental health, spiritual wellness, pediatric cancer, nutritional therapies, alternative medicine, complementary medicine, oncology, laboratory testing, diet personalization Disclaimer: The views expressed in the RWS Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of Restorative Wellness Solutions, LLC. Restorative Wellness Solutions, LLC does not specifically endorse or approve of any of the information or opinions expressed in the RWS Clinician's Corner series. The information and opinions expressed in the RWS Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. Restorative Wellness Solutions, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the RWS Clinician's Corner series. By viewing or listening to this information, you agree to hold Restorative Wellness Solutions, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.
Cancer therapies can save lives, but they often come with tough side effects that aren’t always fully addressed. What side effects should you expect from cancer treatments – and how can you manage them? We sat down with Elizabeth J. Cathcart-Rake, MD, an oncologist at Mayo Clinic, to explore how these effects impact patients’ physical, emotional, and financial well-being – and why quality of life deserves just as much attention. From nausea and fatigue to neuropathy and sexual side effects, we explore the most common fears and how to talk with your doctor. You’ll learn how different therapies (chemo, hormonal, immunotherapy, targeted therapy) impact your body, plus practical, evidence-based tools to help you feel like yourself during treatment.See omnystudio.com/listener for privacy information.
Grocery stores often throw away products that are not expired, but that are past their suggested “Best by” date. That may change in Pennsylvania thanks to a new law signed by Gov. Josh Shapiro last week. It's been more than a century since archeologists discovered the tomb of the Egyptian Pharaoh known as King Tut. Several members of the discovery team suffered untimely deaths shortly after, and the myth of the “mummy’s curse” was born. Scientists believe that team may have actually been exposed to a toxic fungus. Now, researchers at the University of Pennsylvania say that same fungus could help fight cancer. A recent three day clinic allowed firefighters in the city of Wilkes-Barre to get screened for cancer. First responders have an increased risk of cancer from so-called forever chemicals known as P-FAS, which can come from firefighting gear and smoke inhalation. Republican Congressman Dan Meuser - who explored a run for Pennsylvania governor - reportedly won't challenge Democratic Governor Josh Shapiro next year, even after getting an endorsement from President Donald Trump. More than 450 wildland firefighters are now prepared to repond to wildfires across Pennsylvania and nationwide after training at Shippensburg University. Firefighters from 11 states attended the week-long training, offered through the Department of Conservation and Natural Resources' Bureau of Forestry. York City's comprehensive plan appears to be stalled... three months after it was last scheduled for a vote by city council members. A draft of the 200-page plan was previously available on the city's website, but it was removed sometime between April and July. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.
Averil Power, CEO Irish Cancer Society and Muireann McColgan, co-founder of Too Young To Be Heard group, discuss the latest Irish Cancer Society data highlighting the delays in cancer care and what regions have longest delays.To listen to the full conversation, press the ‘play' button on this page.
In this enlightening episode of Keeping Abreast, Dr. Jenn sits down with world-renowned surgical oncologist Dr. Francisco Contreras to explore how mindset, metabolic therapy, and integrative medicine can change the cancer care conversation.Guided by the influence of his father, a pioneer in holistic oncology, Dr. Contreras shares his path to becoming a surgeon and his mission to treat not just the disease, but the whole person. From patient empowerment to the limitations of conventional care, this episode offers a deep dive into the emotional, spiritual, and metabolic components of healing.You'll hear how innovative therapies at Oasis of Hope combine conventional medicine with holistic practices—and why patient education is the cornerstone of long-term success.This conversation is filled with hope, science, and practical insights to help you take charge of your healing journey.In This Episode, You Will Learn:How Dr. Contreras's father inspired his holistic cancer care approachWhy mindset and empowerment are critical in healingThe science behind metabolic therapy and low-glycemic nutritionWhat immunotherapy is—and how it's changing cancer outcomesHow alternative and conventional treatments can work togetherWhy movement, habit-building, and diet play vital roles in recoveryThe truth about high-dose vitamin C, off-label meds, and natural remediesHow innovative treatments like dendritic cell vaccines and CAR T cells workWhy patients deserve education, options, and hope
CAR-T cells, a highly activated immune cell, have been used to treat a solid tumor, stomach cancer, for the first time. Yet the fact remains that CAR-Ts are expensive and time consuming to produce. Johns Hopkins Kimmel Cancer Center director … CAR-T cells are an expensive form of cancer treatment, but other techniques may soon supplant them, Elizabeth Tracey reports Read More »
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Breakthrough in Cancer TreatmentExciting news in the world of oncology as a new breakthrough in cancer treatment has been announced. Researchers have discovered a novel therapy that targets specific mutations in cancer cells, leading to significantly improved outcomes for patients. This groundbreaking treatment is set to revolutionize the way we approach cancer care and could potentially save countless lives in the future.## FDA Approval for New DrugIn other news, the FDA has granted approval for a new drug that shows promising results in the treatment of a rare genetic disorder. This drug has undergone rigorous testing and has been shown to be both safe and effective in clinical trials. The approval of this medication represents a major milestone in the field of rare disease treatment and offers hope to patients who previously had limited options for managing their condition.## Collaboration between Pharmaceutical CompaniesA collaboration between two leading pharmaceutical companies has been announced, with the goal of developing innovative therapies for a range of diseases. This partnership brings together the unique expertise and resources of both companies, potentially leading to the discovery of new treatments that could benefit patients worldwide. This collaboration highlights the importance of working together to address unmet medical needs and advance the field of medicine.## Advancements in Gene TherapyExciting advancements have been made in the field of gene therapy, with researchers reporting promising results in early clinical trials. Gene therapy has the potential to treat a wide range of genetic disorders by replacing or modifying faulty genes. These latest developments represent a significant step forward in the field of genetic medicine and offer hope to patients who previously had limited treatment options.## ConclusionIn conclusion, these recent developments in the world of Pharma and Biotech are not only groundbreaking but also offer hope for patients facing serious medical conditions. From breakthroughs in cancer treatment to advancements in gene therapy, the future of medicine is looking brighter than ever. Stay tuned for more updates on these exciting developments as we continue to follow the latest news in Pharma and Biotech.
Onco-Dermatology: Managing Skin Conditions from Cancer Treatment with guest Dr. Jonathan Leventhal July 6, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095
In the news, counting the calories: The UK government want shops to help us put 100 fewer calories in our baskets to beat obesity. So will it work? Also, archaeologists uncover the world's oldest fat factory - it turns out that Neanderthals were processing bones for their grease 125,000 years ago, but why? And on Mars the Curiosity rover captures close-up images of spiderweb-like patterns on the planet surface, but what made them? Listeners are also wondering whether green initiatives really do help to save the planet... Like this podcast? Please help us by supporting the Naked Scientists
Do we have another comet visiting from outside the solar system? What is Oumuamua? Is the Ring of Fire amping up in activity? Is leukaemia genetic? Does exposure to certain chemicals increase your risk of cancer? Why are early health screenings so important? How do you measure the risk of certain health treatments? Dr Chris Smith and Clarence Ford have all the answers... Like this podcast? Please help us by supporting the Naked Scientists
Do we have another comet visiting from outside the solar system? What is Oumuamua? Is the Ring of Fire amping up in activity? Is leukaemia genetic? Does exposure to certain chemicals increase your risk of cancer? Why are early health screenings so important? How do you measure the risk of certain health treatments? Dr Chris Smith and Clarence Ford have all the answers... Like this podcast? Please help us by supporting the Naked Scientists
“Vax to the Future: Cancer Immunity Revolution
Send us a textIt's a common scenario for a cancer patient. They're undergoing treatment and get what's known as a peripherally inserted central catheter or PICC (pronounced “pick”) line to make it more convenient to administer drugs. They are in and out of the hospital or just the clinic frequently to see various providers. The treatment they receive may run down their immune system a little bit. Just having cancer may have damaged their immune system.So then they get an infection.Perhaps it's no big deal. A round of antibiotics may take care of it. However, increasingly, these infections are resistant to antibiotics – something known as antimicrobial resistance or AMR.Then, the patient must wait weeks or even months to resume cancer treatment while the infection is treated. And, all too often, the infection itself may kill the patient. In fact, infections are the second-leading cause of death for cancer patients.Dr. Yehoda M. Martei, Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania, and colleagues have been working to find out just how common these infections are. Among patients hospitalized for treatment, cancer patients were up to twice as likely to get a drug-resistant infection, she and colleagues found. Among outpatients – people getting treatment at clinics or offices but not staying in the hospital – cancer patients had three times the risk of drug-resistant infections.Listen as Dr. Martei tells One World, One Health host Maggie Fox about her findings, what they mean, and what must be done to protect cancer patients and ensure infections don't stop them from getting the treatment they need.
In this episode of The Common Sense MD, Dr. Tom Rogers welcomes back oncologist Dr. Jamal Maatouk for a compelling exploration of cancer care that goes well beyond the basics. Building on their previous holistic discussion of the cancer experience, Dr. Rogers and Dr. Maatouk dive deeper into how cancer treatment decisions are made—from surgery, chemotherapy, and radiation to cutting-edge targeted therapies and immunotherapies like CAR T.Dr. Maatouk shares her philosophy that there is no one-size-fits-all approach in oncology. She highlights the importance of truly getting to know each patient as a whole person, considering their wishes, unique biology, and even their spiritual outlook. The conversation unpacks the difference between immunotherapy and targeted therapy in an easy-to-understand way, as well as when and why oncologists might recommend gentler approaches like dose reductions or integrative support for quality of life.The doctors have an open, honest conversation about the value of second opinions, the evolving science of cancer, and the growing trend of patients taking an active role in their care—including the use of supplements and alternative therapies. Dr. Maatouk powerfully expresses her belief in the innate ability of the human body to heal, the role of hope and love in medicine, and her commitment to supporting each patient on their own unique healing journey.If you or a loved one are navigating cancer—or simply want a refreshing, compassionate take on modern medicine—this episode is an inspiring reminder that healing is possible, and that true care starts with listening, empathy, and hope.What did you think of this episode of the podcast? Let us know by leaving a review!Connect with Performance Medicine!Check out our new online vitamin store:https://performancemedicine.net/shop/Sign up for our weekly newsletter: https://performancemedicine.net/doctors-note-sign-up/Facebook: @PMedicineInstagram: @PerformancemedicineTNYouTube: Performance Medicine
Vanessa Penna left Brazil in 2015 to pursue a PhD in neuroscience at the University of Melbourne, with a scholarship from the Australian government. Six years later, she was awarded the prestigious Global Talent visa, now known as the National Innovation visa (subclass 858), for her scientific work. She now manages clinical trials of new drugs that hold promise for cancer patients. During this journey, she was the third person in the world to be diagnosed with Pure HSP 5A, a rare condition that led her to use a wheelchair. - Vanessa Penna deixou o Brasil em 2015 para cursar doutorado em neurociência na Universidade de Melbourne, com bolsa do governo australiano. Seis anos depois, conquistou o prestigiado visto de Talento Global, agora chamado visto de Inovação Nacional (subclasse 858), por conta de seu trabalho científico. Hoje, ela gerencia ensaios clínicos com novos medicamentos que dão esperança a pacientes com câncer. Durante essa trajetória, foi diagnosticada com uma doença rara, a HSP 5A pura, condição que a levou a usar cadeira de rodas.
- Overview of Liver Cancer, Including Current Standard of Care - New Treatment Approaches - Clinical Trial Updates: How Research Increases Your Treatment Options - The Role of Radioembolization - Controlling Symptoms, Treatment Side Effects, Discomfort & Pain - Nutrition & Hydration Concerns & Tips - Communicating with Your Health Care Team About Your Financial Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments, Quality-of-Life Concerns & Discussion of OpenNotes - Questions for Our Panel of Experts
Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News. I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC. Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings. So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease. So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting. So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting. So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response. So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma. So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025. So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence. So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj. Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer. So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response. These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months. Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup. So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj. Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial. A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion. So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance. So, thank you, Jeanny, for joining me today and sharing your insights. And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Neeraj Agarwal @neerajaiims Dr. Jeanny Aragon-Ching Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis, Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics
Can addressing the body's metabolism really make a difference in cancer care? Henning Saupe, MD, author of Holistic Cancer Medicine, and founder of Arcadia Praxisklinik, believes it can, and must. After witnessing the toll conventional treatments took on his mother, Dr. Saupe was inspired to explore a gentler, more supportive path. He now helps patients […]
Supporting someone going through cancer - what's the best way to do it when you don't know what to say? Ruth Fein has a bunch of interesting titles. Medical/science reporter. Award-winning author. Patient engagement leader. Motivational speaker. Ruth is a globally recognized patient advocate leader with a proven track record bringing together the voice of the patient, not-for-profit sector, industry and academia in the hematology/oncology space. In episode 579 of the Fraternity Foodie Podcast, we find out why Ruth chose Utica College for her undergraduate experience, how her rare blood cancer shaped her work as a journalist and patient advocate, what inspired her to write The Big C² and how it's different from other books, what is the best way to support someone going through cancer, how you can recognize red flags in your own health, what are some phrases to avoid when talking to someone who has cancer, what tools or perspectives have helped people she's interviewed to move forward, how to make the most of that time with doctors and truly advocate for themselves, and what college students need to know about the future of cancer treatment.
In this episode of The Common Sense MD, Dr. Tom Rogers welcomes esteemed oncologist Dr. Jamal Maatouk for an inspiring and deeply honest conversation about cancer treatment, the role of lifestyle in health, and the importance of treating the whole person—mind, body, and soul. Dr. Maatouk shares her unique journey from Lebanon to the U.S., the challenges and rewards of practicing oncology, and her faith-driven approach to guiding patients through both healing and end-of-life care. Together, they explore the rising trends in cancer diagnoses, the impact of environment and mindset, and how physicians can balance science, art, and empathy in their practices. Join this powerful discussion on hope, healing, and the common-sense steps we can all take to prevent disease and live more vibrant lives.What did you think of this episode of the podcast? Let us know by leaving a review!Connect with Performance Medicine!Check out our new online vitamin store:https://performancemedicine.net/shop/Sign up for our weekly newsletter: https://performancemedicine.net/doctors-note-sign-up/Facebook: @PMedicineInstagram: @PerformancemedicineTNYouTube: Performance Medicine
More types of gut bacteria, or greater diversity, the healthier your microbiome. That's one message of a recent review looking at the impact of microbiome health on cancer. Kimmel Cancer Center director William Nelson at Johns Hopkins explains how gut … Which types of cancer treatment are impacted by the gut microbiome? Elizabeth Tracey reports Read More »
What if a free, side-effect-free therapy could significantly improve your cancer survival— and even help prevent recurrence? In this episode, we explore the powerful, research-backed role of exercise in cancer prevention and treatment, centered around the recent CHALLENGE trial published in The New England Journal of Medicine. Here is the link to that study: https://www.nejm.org/doi/10.1056/NEJMoa2502760 Dr. Hassell shares groundbreaking findings showing that moderate, consistent exercise significantly reduces cancer recurrence and mortality — particularly in colon cancer survivors — when added to conventional treatments. More than just prevention, movement is positioned as a critical treatment tool that enhances immunity, reduces inflammation, balances hormones, and even boosts mental health. Key Takeaways: Exercise led to a 37% lower risk of death in colon cancer patients (CHALLENGE trial). Benefits appear as early as 1 year into a structured program (as little as brisk walking!). Sedentary lifestyles are now considered nearly as dangerous as smoking. Even 1-minute workouts a few times a day can start improving immune function. The “number needed to treat” for exercise is dramatically better than many standard medical therapies. Physical activity also reduces risk of diabetes, heart disease, depression, frailty, and more. Social, playful exercise (like frisbee or ping pong) boosts both body and mind — and reduces loneliness. Watch now to discover how just a few minutes of movement a day could change — or even save — your life. #CancerTreatment #ExerciseAndCancer #PreventativeHealth #ChallengeTrial #LifestyleMedicine #WalkDontRunPodcast #MentalHealth #ChronicDiseasePrevention More references can be found at www.GreatMed.org Would you like Dr. Hassell to answer your question on the air? Contact us! Phone/text: 503-773-0770 e-mail: info@GreatMed.org Write us a letter. We love to hear from you. This podcast is sponsored by our generous listeners. Send questions, comments, and support to: 4804 NW Bethany Blvd., Suite I-2, #273 Portland OR 97229
This is episode three of Swimming with Shadows: A Radiolab Week of Sharks.Today, we take a trip across the world, from the south coast of Australia to … Wisconsin. Here, scientists are scouring shark blood to find one of nature's hidden keys, a molecular superhero that might unlock our ability to cure cancer: shark antibodies. They're small. They're flexible. And they can fit into nooks and crannies on tumors that our antibodies can't.We journey back 500 million years to the moment sharks got these special powers and head to the underground labs transforming these monsters into healers. Can these animals we fear so much actually save us? Special thanks to Mike Criscitiello, David Schatz, Mary Rose Madden, Ryan Ogilvie, Margot Wohl, Sofi LaLonde, and Isabelle Bérubé.EPISODE CREDITS: Reported by - Becca BresslerProduced by - Becca Bressler and Matt KieltyOriginal music from - Matt Kielty and Jeremy BloomSound design contributed by - Matt Kielty, Jeremy Bloom, and Becca Bresslerwith mixing help from - Jeremy BloomFact-checking by - Diane Kellyand Edited by - Pat WaltersSignup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)!Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today.Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Gordon and Betty Moore Foundation, Science Sandbox, a Simons Foundation Initiative, and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.
Stem Cell Therapy, Longevity & Regenerative Healing with Joshua Ketner Josh Ketner is a pioneer in the field of regenerative medicine. Josh is not only the insightful author of 'The Ultimate Guide to Stem Cell Therapy,' but he's also the visionary founder of Dream Body Clinic, nestled in tropical Puerto Vallarta, Mexico. At Dream Body Clinic, Josh and his team specialize in cutting-edge treatments like mesenchymal stem cell therapies, along with Human Growth Hormone (HGH) and other innovative age-defying medicines. In this powerful episode, we sit down with Joshua Ketner, founder of DreamBody Clinic in Mexico, to explore how stem cell therapy is transforming the future of health and longevity. Episode highlights: ✔ How stem cells work (hint: they're not what you think) ✔ Why patients are traveling to Mexico for affordable regenerative care ✔ Conditions treated: arthritis, autoimmune diseases, organ issues & more ✔ Success stories that defy the odds and how treatments can add quality years to your life. ✔ How hormone therapy & DNA methylation testing support anti-aging ✔ The truth about safety, U.S. regulations, and stem cell myths Chapters 06:23 Understanding Stem Cells, the sciene and Their Function 17:31 Common Conditions Treated at DreamBody Clinic 19:40 Addressing Skepticism and Success Stories 20:39 Treatment Process and Patient Experience 22:34 Safety and Side Effects of Treatments 30:27 Safety and Efficacy of Stem Cells in Cancer Treatment 33:26 Success Stories: Overcoming Autoimmune Conditions 36:55 Preventative Measures for Longevity 41:34 The Importance of Blood Work for Weight Loss 43:06 Understanding Treatment Costs and Transparency This conversation breaks down complex science into actionable insights for anyone seeking pain relief, age reversal, and optimal health. Helpful links and resources: Learn about Dream Body Clinic https://www.youtube.com/@DBCStemCells Purchase Joshua's book here FB: facebook.com/dreambodyclinic IG: @clinicdreambody
Has cancer ever made you feel like you're losing a piece of yourself, especially your identity? Imagine facing hair loss from treatment, only to find the wig options available don't reflect who you are. This isn't just about hair; it's about dignity, self-esteem, and seeing yourself truly represented.In this powerful rebroadcast, join your host, Talaya Dendy, on Navigating Cancer TOGETHER as she welcomes the incredible Dianne Austin. A breast cancer survivor herself, Dianne co-founded Coils to Locs, a groundbreaking initiative born out of a deeply personal struggle. Prepare to be inspired by her journey to transform the wig industry and support women of color facing hair loss due to cancer and other medical conditions.
Caris Life Sciences (CAI) CEO Brian Brille discusses their IPO and using AI in medical care. Caris is a precision oncology company that offers personalized treatment using genomic sequencing and data. “We're a pioneer in genomics…more information equals more power.” He explains the company's process and why AI is a useful tool in the field. He also talks about their unusual partnership structures with other companies.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about
In this episode of Breaking Health, host Steve Krupa speaks with Matt Bettonville, investor at Yosemite, about the state of oncology research and his hunt for investments in discovery and treatment tools. Bettonville delves into the key to cancer treatment, where deals are flowing towards in the market, and how the AI revolution is helping with drug discovery and cancer treatment breakthroughs. He also discusses the complications (and frustrations) of making treatments affordable, finding new targets in primary cancers most frequently seen in the population, and the importance of early detection. Links from this episode: HealthEdgeYosemite
EVEN MORE about this episode!Let's explore the incredible intersection of spiritual insight and physical healing! From foot pain relief in Australia to emotional support during brain cancer treatment in Connecticut, witness how intuition, visualization, and collective energy can shift pain and promote healing.Discover the hidden emotional roots of illness, how intuitive scans reveal what doctors often can't, and why our pets may be mirroring our health. Whether it's helping a child with special needs, soothing an anxious dog owner, or clearing energy blocks that contribute to chronic symptoms—this episode is a moving journey into what's truly possible when we combine intention with intuition.Plus, get a sneak peek at my upcoming Angelic Attendant Training—an immersive experience that could change your life. Don't miss this transformative episode that just might open your mind to a whole new way of healing!Episode Chapters:(0:00:01) - Psychic Healing(0:14:40) - Cancer Healing Energy Session(0:23:56) - Healing Energy for Eye Conditions(0:36:54) - Group Session for Hearing Loss(0:49:54) - Healing Consultation(0:59:09) - Healing Energy for Cancer Treatment(1:05:36) - Messages From Sweet Home Alabama➡️Subscribe to Ask Julie Ryan YouTube➡️Subscribe to Ask Julie Ryan Español YouTube➡️Subscribe to Ask Julie Ryan Português YouTube➡️Subscribe to Ask Julie Ryan Deutsch YouTube➡️Subscribe to Ask Julie Ryan Français YouTube✏️Ask Julie a Question!
In this thought-provoking episode of the Spectrum of Health podcast, Dr. Christine Schaffner welcomes Dr. Jack Tuszynski, a leading biophysicist and researcher in the emerging field of quantum biology. This conversation, recorded during the Quantum Coherence Medicine Masterclass, explores the fundamental role of quantum mechanics in human biology and consciousness. Dr. Tuszynski shares fascinating insights into microtubules, cellular communication, and the science behind how coherence and quantum fields may influence healing. Together, they discuss the convergence of physics and medicine—and how future health innovations could be shaped by our deepening understanding of quantum processes in the body.
Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, AppleTV or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Nicole: Willingness to take bold leaps and embrace the unknown.Imagine a world where cancer is as treatable as the flu. That's the vision Nicole Paulk, the founder and CEO of Siren Biotechnology, is working tirelessly to bring to life. Driven by groundbreaking science, Nicole's company is on the brink of launching clinical trials for a revolutionary cancer treatment.Nicole's work leverages engineered viruses—those that don't make you sick—to deliver genetic medicines directly to cancer cells. These “good viruses” act as a delivery system for anti-tumor drugs, targeting difficult-to-treat cancers like recurrent high-grade gliomas, a fatal brain cancer. “We started to see data that looked really promising in this space,” Nicole explained, adding, “We felt a moral obligation to go after this cancer where there's just this huge unmet need.”Siren Biotechnology's approach is designed to have broad applications. Unlike treatments that target specific genetic mutations, their method has the potential to work on various tumor types. Nicole describes it as using viruses like a “little FedEx delivery truck” that can be engineered to deliver medicine precisely where it's needed in the body.This innovation didn't happen overnight. Nicole, a former professor of virology at UCSF, took the bold step of leaving academia to launch Siren Biotechnology. “I decided to resign from my faculty position and go be the founder and CEO just because I was so excited about the data and what we had so far,” she shared.In addition to traditional venture capital funding, Siren Biotechnology is inviting the public to invest through a regulated investment crowdfunding campaign. This unique opportunity allows patients, families, and supporters touched by cancer to be part of their journey. “We wanted to bring patients and their families onto our cap table,” Nicole said. “It's a way to involve them in the conversation much earlier.”Siren Biotechnology's work could redefine cancer care and inspire a new model for patient-centered innovation. With clinical trials just months away, the future looks brighter for those battling cancer—and for all of us who dream of a world where cancer is no longer a death sentence.tl;dr:Nicole Paulk's Siren Biotechnology transforms viruses into targeted cancer therapies with universal potential.The company focuses on recurrent high-grade gliomas, a fatal brain cancer with no standard treatment.Nicole left academia to lead Siren, leveraging her groundbreaking virology research to launch the company.Siren's unique crowdfunding campaign lets patients and families invest in the fight against cancer.Nicole's superpower, fearless innovation, drives her bold mission to revolutionize cancer care.How to Develop Fearless Innovation As a SuperpowerNicole's superpower is her willingness to take bold leaps and embrace the unknown. After spending nearly two decades building her academic career, Nicole left her position as a virology professor at UCSF to start Siren Biotechnology. She explained, “I feel like my superpower is just kind of being willing to jump off the cliff without a parachute and be like, we're going to figure it out. We're going to make it work.”Nicole exemplified fearless innovation when her research led to a groundbreaking discovery about the biology of a virus, one that required rewriting existing textbooks. Initially met with skepticism, her work was later validated and became a foundation for Siren Biotechnology's cancer treatment. This pivotal moment highlights Nicole's courage to challenge conventional knowledge and pursue transformative ideas.Tips for Developing This Superpower:Be willing to question conventional wisdom and explore new paths.Take calculated risks, even if it means stepping away from a well-defined career path.Embrace discomfort and uncertainty as a necessary part of innovation.Engage others by communicating your vision in relatable and accessible ways.By following Nicole's example and advice, you can make fearless innovation a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileNicole Paulk (she/her):CEO, Founder, President, Siren BiotechnologyAbout Siren Biotechnology: We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy – into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.This is the first AAV gene therapy drug product that can be made once and used in numerous indications – a huge leap forward for the field. This drastically reduces clinical development times, manufacturing timelines, and capital needs for each clinical trial. Most importantly, ‘universal' means countless solid tumor cancer patients – regardless of tumor type or mutations – may benefit from this breakthrough approach.Website: sirenbiotechnology.comX/Twitter Handle: @SirenBioCompany Facebook Page: facebook.com/SirenBiotechnologyOther URL: wefunder.com/siren.biotechnologyBiographical Information: Dr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. With nearly two decades of expertise, Nicole has been at the forefront of developing cutting-edge advances to propel the field of gene therapy forward for a wide range of diseases.Before founding Siren, Nicole held various leadership positions in academia and industry and most notably was an Assistant Adj Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren. Nicole has a B.S. in Medical Microbiology, a Ph.D. in Viral Gene Therapy and Regenerative Medicine from OHSU, and completed her Postdoctoral Fellowship and Instructorship in Human Gene Therapy at Stanford University prior to starting her lab at UCSF. Nicole is a pioneer in the development of next-generation AAV platforms for gene repair, gene transfer and gene editing, directed evolution for novel engineered capsid evolution, and comparative multi-omic approaches to interrogate translational AAV biology.Nicole is a renowned expert in gene therapy and has consulted extensively for big pharma, written draft CMC guidance for the FDA, and sits on the Scientific Advisory Boards for Sarepta, Astellas, Metagenomi, Dyno Therapeutics, CEVEC, GRO Biosciences, Excision BioTherapeutics, WhiteLab Genomics, Johns Hopkins Gene Therapy Initiative, the Gene Therapy for Rare Disorders Searchlight Program, and several stealth startups. She has been quoted in The Wall Street Journal, The Economist, The Boston Globe, Endpoints, STAT, Phacilitate, GEN, BioPharma Dive, Evaluate Vantage, SF Business Times, WIRED, Drug Discovery World, MIT Tech Review, C&EN, and more. She sits on the Scientific Editorial Boards of the journals Gene Therapy, Human Gene Therapy, and Biopharma International Gene Therapy. She is the Chair of the American Society of Gene and Cell Therapy (ASGCT) Translational Science Committee, and a member of the ASGCT Cancer Cell and Gene Therapy Committee and the Biocom California Cell and Gene Therapy Committee. She has invented numerous AAV gene therapy technologies that have been shared or licensed to dozens of gene therapy companies and nonprofit groups working in rare diseases.Outside of work, you can find Nicole adventure traveling (think whitewater rafting meets backcountry trekking), snowboarding, planning elaborate Halloween parties complete with animatronics and ghoulish menus, tending her vegetable garden, and obsessing over the latest wearable gadgets. If you're trying to track her down at a conference and can't find her, it's because she snuck off to an oyster bar.X/Twitter Handle: @Nicole_PaulkLinkedin: linkedin.com/in/nicolepaulkInstagram Handle: @sirenbioSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Kingscrowd and Crowdfunding Made Simple. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support:Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on June 17, 2025, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, June 18, 2025, at 12:00 PM Eastern. Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), will lead a session on "How to Spin $1 of Advertising into $10!" He'll reveal proven strategies and marketing insights drawn from years of experience helping successful crowdfunding campaigns. Whether you're a founder planning a raise or a supporter of innovative startups, you'll gain actionable tips to boost visibility, drive engagement, and hit your funding goals. Don't miss it!Join us on June 25, 2025, at 8:00 PM Eastern for the Superpowers for Good Live Pitch—streaming on e360tv, where purpose-driven founders take the virtual stage to present their active Regulation Crowdfunding campaigns to a national audience of investors and changemakers. Selected startups are chosen for their commitment to community, alignment with NC3's Community Capital Principles, and their drive to create real-world impact. Thanks to sponsors DNA and DealMaker, this event is free to watch and amplifies the voices of underrepresented and mission-aligned entrepreneurs. Don't miss this inspiring evening where capital meets purpose—tune in to discover and support the next wave of impact-driven innovation.SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We'll be streaming live across the web and on TV via e360tv. Soon, we'll open a process for nominating speakers. Check back!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com's monthly crowdfunding workshop, where he'll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern. Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.Call for community action:Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefiting both the investors and the small businesses that receive the investments. Learn more here.If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe
Physician and clinical researcher Chris Apfel discusses his article, "Functional precision oncology: a game changer in cancer therapy." Chris explains that functional precision oncology takes a highly personalized approach by testing a patient's live tumor cells outside the body (ex-vivo) against a panel of cancer drugs to directly observe which treatments are most effective against that specific cancer. This method, he argues, can significantly improve cancer response rates and survival while reducing costs and unnecessary side effects, by moving beyond the limitations of standard pathology (which identifies cancer type but not optimal treatment) and genomic sequencing (which identifies mutations but provides actionable targets for only a minority of patients). Chris recounts the history of functional testing, its initial promise, its decline with the rise of next-generation sequencing, and its current resurgence, supported by studies demonstrating its high predictive accuracy for clinical outcomes. Despite its potential to complement genomics and truly personalize care, he notes that functional precision oncology faces slow adoption due to its general absence from standard NCCN treatment guidelines, hospital restrictions on external tissue testing, and a systemic preference in health care for standardization over innovative, individualized approaches. Chris strongly encourages patients, particularly those facing difficult or unresponsive cancers, to educate themselves about functional precision oncology and actively advocate for access to these tests. Our presenting sponsor is Microsoft Dragon Copilot. Want to streamline your clinical documentation and take advantage of customizations that put you in control? What about the ability to surface information right at the point of care or automate tasks with just a click? Now, you can. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Offering an extensible AI workspace and a single, integrated platform, Dragon Copilot can help you unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise and it's part of Microsoft Cloud for Healthcare–and it's built on a foundation of trust. Ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended
Register free at https://brightu.com to watch the full Healing Revolution stream - Breaking News and Upcoming Segments (0:00) - Microscopy of Bio Sludge (2:04) - Bio Sludge as a Vector for Bioterrorism (4:03) - Details of the Chinese Couple's Case (7:23) - Potential for Bioterrorism and EPA's Role (11:51) - Microscopy of Bio Sludge: Dry Condition (17:54) - Microscopy of Bio Sludge: Incubated Condition (39:25) - Moderna Vaccine Approval and RFK Jr. (53:26) - Elon Musk's Criticism of Trump's Bill (1:07:07) - Ukraine War and Financial Corruption (1:12:41) - AI and Humanity's Future (1:17:40) - Self-Awareness in Life Forms (1:20:40) - Artificial Intelligence and Self-Awareness (1:27:51) - The Potential Dangers of AI (1:32:30) - AI's Impact on Infrastructure and Society (1:37:07) - The Role of Light in Healing (1:46:09) - The Healing Revolution Docu Series (1:47:06) - The Importance of Combining Therapies (1:50:03) - The Role of Light in Activating Nutrients (1:51:34) - The Impact of Light on Cancer Treatment (2:33:08) - The Role of Light in Detoxification (2:35:26) - LED vs. Incandescent/Halogen Bulbs (2:36:33) - Wavelengths and Their Therapeutic Benefits (2:38:13) - Dual LED Technology and Natural Intelligence (2:39:45) - Practical Applications and Humanitarian Efforts (2:42:09) - Healing Revolution Course and Additional Resources (2:45:53) - Long COVID Study and Remission Rates (2:47:42) - Final Thoughts and Call to Action (2:50:30) - Health Ranger's Preparedness Tips (2:51:47) - Iodine Supplements and Their Benefits (2:56:14) - Conclusion and Final Remarks (2:58:12) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com
© 2020-2025 Ivy Podcast Discovery LLC
